Lyra Therapeutics is a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, offering an alternative to conventional treatments or surgeries. The company's lead drug candidate, LYR-210, offers a novel approach for directing anti-inflammatory medicine deep into sinonasal tissues for up to six months of therapy. With proprietary expertise in drug development and materials science, Lyra is applying its transmucosal therapeutic system - comprised of drug administered through a polymeric matrix - with the goal of enabling therapeutic action at the site of inflammation in the sinonasal passages.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/26/18	$29,500,000	Series B	ArrowMark Partners Perceptive Advisors RA Capital Management Soleus Capital	undisclosed
01/29/20	$30,000,000	Series C	ArrowMark Partners Clifton Capital Intersouth Partners North Bridge Venture Partners Perceptive Advisors Polaris Partners RA Capital Management Soleus Capital	undisclosed